|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice lacking PTP-1B are resistant to both diabetes and obesity.
|
10665340 |
1999 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These very preliminary findings suggest that genomic variation in PTP-1B is associated with a reduced risk of diabetes and are consistent with the idea that this protein is important in metabolism.
|
11836311 |
2002 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, PTP1B is being investigated by a number of companies as a promising target for leptin/insulin mimetics and in the treatment of diabetes and obesity.
|
12472377 |
2002 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we review the function of PTP1B and TC-PTP in diabetes, obesity, and processes related to cancer.
|
16198645 |
2005 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PTPN1, a diabetes susceptibility gene, was investigated for a role in diabetic atherosclerosis.
|
16505227 |
2006 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The emergence of protein-tyrosine phosphatase 1B (PTP1B) as a potential drug target for treatment of diabetes, obesity, and cancer underlies the importance of understanding its full range of cellular functions.
|
18387954 |
2008 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Validation of PTP1B as a therapeutic target for obesity and diabetes prompted efforts to develop potent and selective inhibitors of PTP1B.
|
23374726 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein-tyrosine phosphatase 1B (PTP1B) is a physiological regulator of glucose homeostasis and adiposity and is a drug target for the treatment of obesity and diabetes.
|
23640882 |
2013 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, these results indicate that, although inhibition of PTP1B has potential benefits for the treatment of diabetes, it accentuates pro-inflammatory responses compromising at least macrophage viability.
|
24625984 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTP1B, a validated therapeutic target for diabetes and obesity, has a critical positive role in HER2 signaling in breast tumorigenesis.
|
24845231 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) is known to promote the pathogenesis of diabetes and obesity by negatively regulating insulin and leptin pathways, but its role associated with colon carcinogenesis is still under debate.
|
27752061 |
2016 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trivaric acid, a new inhibitor of PTP1b with potent beneficial effect on diabetes.
|
27871946 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.
|
27872190 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
All of the new compounds showed promising PTP1B inhibitory activities with IC<sub>50</sub> values comparable to the positive control, indicating them as potential food additives or pharmaceutical drug leads toward obesity or diabetes.
|
28173704 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show how these pillars are connected in Protein Tyrosine Phosphatase 1B (PTP1B), a drug target for diabetes and cancer that catalyzes the dephosphorylation of numerous substrates in essential signaling pathways.
|
28212750 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) plays important role in diabetes, obesity and cancer.
|
28318895 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
To unveil the structure-activity relationship of a naturally occurring flavonoid, we investigated the effects of the glycosylation of naringenin on the inhibition of enzyme systems related to diabetes (protein tyrosine phosphatase 1B (PTP1B) and α-glycosidase) and on glucose uptake in the insulin-resistant state.
|
28454670 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTP1B has been known as a strategy for the treatment of diabetes via the regulation of insulin signal transduction pathway.
|
28499188 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential therapies for diabetes and obesity have attracted much attention in recent years.
|
28642102 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase are important targets to treat obesity and diabetes, due to their deep correlation with insulin and leptin signalling, and glucose regulation.
|
28933230 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, ferulic acid exhibited beneficial effects on diabetes-induced cognition lesions, which was involved in the regulation of PTP1B and insulin signaling pathway.
|
28988132 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein-tyrosine phosphatase PTP1B is a negative regulator of insulin and leptin signaling and a highly validated therapeutic target for diabetes and obesity.
|
29217773 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant PTP1B is associated with obesity, diabetes, cancers, and neurodegenerative disorders.
|
29235148 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and α-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity.
|
29306546 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This work illustrates a novel paradigm for inhibiting the signaling function of PTP1B that may be exploited for therapeutic intervention in diabetes and obesity.
|
29348454 |
2018 |